NanoRepro AG (ETR:NN6)

Market Cap	19.42M
Revenue (ttm)	3.56M
Net Income (ttm)	-3.20M
Shares Out	12.61M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40
Average Volume	6,810
Open	1.485
Previous Close	1.540
Day's Range	1.485 - 1.485
52-Week Range	1.170 - 2.250
Beta	0.02
RSI	42.82
Earnings Date	Jul 9, 2025

About NanoRepro AG

NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, such as family planning, and preventive healthcare line products; tests for hospitals and medical practices to detect aids, Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and mi...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2006
• Employees: 18
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: NN6

Financial Performance

In 2023, NanoRepro AG's revenue was 3.18 million, a decrease of -91.79% compared to the previous year's 38.79 million. Losses were -4.69 million, 25.8% more than in 2022.